Artal Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Artal Group’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-50,000	Closed	-$1.45M	–	132
2017 Q4	$1.45M	Buy	+50,000	New	+$1.32M	0.02%	107

Other funds holding RYTM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group's RYTM Position: Q1 2018 in Review

Artal Group sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2018, closing a stake of 50,000 shares — an estimated $1.45M sold.

Artal Group first reported a position in RYTM in Q4 2017 and held it in 1 quarter. The position peaked at $1.45M in Q4 2017. 55 funds tracked by Wall St. Rank hold RYTM as of Q1 2018.

Artal Group reported no remaining Rhythm Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Artal Group sold 50,000 Rhythm Pharmaceuticals shares in Q1 2018, an estimated $1.45M.
Artal Group first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Artal Group's Rhythm Pharmaceuticals position peaked at $1.45M in Q4 2017.
55 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.